Group items tagged

In a significant leap forward in the fight against HIV, the Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to two groundbreaking formulations of cabotegravir. Apretude 30 mg film-coated tablets and Apretude 600 mg prolonged-release suspension for injection are now authorized for preventing sexually transmitted HIV-1 infection in adults and adolescents weighing at least 35kg at increased risk. This approval marks a pivotal moment in HIV (human immunodeficiency virus) prevention, offering an alternative to existing standard pre-exposure prophylaxis or PrEP treatments. HIV, a virus notorious for compromising the immune system, has long been a global health concern. Cabotegravir, a member of the integrase inhibitor group, works by blocking a key enzyme necessary for the replication of HIV-1, thereby reducing the virus's ability to spread.

In its first, the National Institute for Health and Care Excellence (NICE) has recommended the use of Pre Exposure Prophylaxis (PrEP) to treat people at the highest risk of catching HIV. The announcement comes along with a consultation on draft guideline by NICE on reducing sexually transmitted infections. NICE's recommendation is backed up by the government's HIV Action Plan to hit zero new transmissions of HIV by 2030. The pill prevents HIV by stopping the virus from crossing into the healthy cells and replicating. According to the UK PROUD study, PrEP reduced the risk of HIV infection by 86 per cent for men who have sex with men. However, people taking the pill must also get regular HIV testing and STI screening done every three months.

At the European Conference of Clinical Microbiology & Infectious Diseases (ECCMID) this year in Copenhagen, Denmark, data on a test that may detect HIV, hepatitis B, and hepatitis C from a single drop of blood are being presented. Hepatitis B or C claim the lives of over a million people each year. Every year, 1.5 million individuals contract HIV, and 650,000 people pass away from HIV-related causes. The World Health Organisation has made the elimination of all three viruses by 2030 one of its global health strategies but new tests are necessary if case numbers are to be reduced. The most common test for hepatitis B, hepatitis C and HIV involves taking a blood sample from a vein using a needle. While this method works extremely well, there is a potentially large reservoir of the three conditions in places where this method is not suitable. This could be prisons, drug rehabilitation centres and homeless shelters, where the taking of venous blood samples isn't always suitable or countries in which the shipping and refrigerated storage of blood samples can be challenging. Alternatives include dried blood spot tests, in which a single spot of blood is tested for nucleic acid from the three viruses.

Taking treatment properly during pregnancy and breastfeeding will keep your baby free of HIV. Despite the ongoing use of #HIV medicines after childbirth, a woman with HIV can still pass HIV to her baby while breastfeeding. The use of HIV medicines and other strategies have helped to lower the rate of mother-to-child #transmission of HIV to 1% or less. As every person's situation is different, it is best to talk to a #healthcare professional to get specific advice. For more info visit our website: https://drpounders.com

British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur. The injected drug cabotegravir is approved by regulators in Britain and the United States. Last July, GSK announced a program with the United Nations-backed healthcare organisation, the Medicines Patent Pool, aiming to get poor countries access to new HIV therapies far earlier than they did for previous HIV medicines. During the HIV/AIDs epidemic in Africa in the 1990s and early 2000s, in which many millions of people died, treatments used widely in wealthy countries were unavailable on the continent. GSK said last year the new program could result in the generic form of its injection being available in lower-income countries beginning in 2026. The drugmaker's HIV treatment division, ViiV Healthcare, said in a statement on Wednesday it had issued voluntary licenses - waiving intellectual property rights - to Aurobindo, Cipla and Viatris, which will manufacture the generic versions of injectable cabotegravir.

HIV-related stigma and discrimination refer to prejudice, negative attitudes, and abuse directed at people living with #HIV and #AIDS. Stigma and discrimination also make people vulnerable to HIV. HIV/AIDS must be defeated with trust, openness, dialogue between individuals, and family support. Stop HIV stigma and find new paths and solutions. For further information visit our site: https://www.drpounders.com/

There has been significant success in reducing the number of new HIV infections among children since 2000, except for children living with HIV, AIDs-related illnesses are still among the leading causes of infant mortality. Regular HIV testing, treatment, monitoring, and care for children living with HIV can enable them to live long and fulfilling lives. More is needed to support the prevention of HIV among vulnerable children. Visit our website https://drpounders.com/ or Call Us at 214-520-8833

Johnson & Johnson said on Wednesday (January 18) that it was pulling the plug on a late-stage global trial of an HIV vaccine after the shot was found ineffective at preventing infections. The failure of the trial marks yet another setback in the search for a vaccine against a virus known to mutate rapidly and find unique ways to evade the immune system, and comes more than a year after another of J&J's HIV vaccine failed a study. "It's not the outcome we had hoped for, unfortunately," said a spokesperson for the National Institute of Allergy and Infectious Diseases, a J&J partner in the trial. "The development of a safe and effective HIV vaccine has been a considerable scientific challenge, but we will learn from this study and continue forward." The trial involved administering two different types of a shot, which uses a cold-causing virus to deliver the genetic code of HIV, spread over four vaccination visits in a year. J&J used similar technology for its COVID-19 vaccine. The study, which began in 2019, was conducted at over 50 sites and included about 3,900 gay men and transgender people - groups that are considered vulnerable to the infection.

The outlook for people living with #HIV has significantly improved over the past two decades. Many people who are living with HIV can now live much longer, healthier lives when regularly taking HIV treatment. #Medications can help to slow damage. That's why routine HIV screening is vital. Early detection and timely #treatment are essential in managing the virus, extending life expectancy, and reducing the risk of #transmission. For more information click our Website link: https://www.drpounders.com/ or call us +1 214-520-8833

Pre-exposure prophylaxis (PrEP) is a course of HIV drugs taken by HIV-negative people to protect them against HIV. If used consistently and correctly, PrEP will virtually eliminate the risk of you getting HIV. While you're taking PrEP, you should visit your healthcare professional for regular check-ups. For More Info Visit Our Website: https://drpounders.com/ or Call Us at 214-520-8833

HIV continues to have a disproportionate impact on specific populations, particularly racial and ethnic minorities and gay and #bisexual men. However, with increasing access to effective HIV prevention and diagnosis, HIV has become a manageable chronic health condition, enabling people living with HIV to lead long and healthy lives. For More Information Website: https://drpounders.com/ or Call Us at 214-520-8833

Most of the Race / Ethnicity Americans have been directly affected by HIV/AIDS as the epidemic's start. Many challenges add to the epidemic between different Races / Ethnicity, including lack of access to proper health care, poverty, a large amount of sexually transmitted infections, smaller sexual networks, lack of information about the HIV situation, and stigma. We should treat everyone equally and fight together to defect HIV/AIDS from its root. Visit Our Website: https://drpounders.com/ or Call Us at 214-520-8833

In its first, the National Institute for Health and Care Excellence has recommended the use of long-acting injectable treatment for HIV-1 infection in adults, making around 13,000 people eligible for treatment with cabotegravir with rilpivirine in England. The new treatment aims to keep the number of virus particles in the blood so low that it cannot be detected or transmitted between people. Current treatment for HIV‑1 is lifelong antiretroviral tablets taken each day. Use of cabotegravir with rilpivirine is recommended when there is no evidence tosuspect viral resistance, and no previous failure of other anti-HIV-1 medicines. "Clinical trial results show that cabotegravir with rilpivirine is as effective as oralantiretrovirals at keeping the viral load low," NICE stated. Both are administered as two separate injections every two months, after an initial oral (tablet) lead-in period.

#HIV is a virus that damages the immune system. It is a lifelong condition and without treatment, a person with HIV can develop AIDS, which makes the #immunesystem severely compromised. An HIV diagnosis is life-changing. But with the right care, you can enjoy a long, healthy life. For more info visit Website: https://www.drpounders.com/ or call us (214) 520-8833 #healthcare #livingwithHIV #staystrong #pcp #PrEP #drpounders #hivprevention #hivdoctors #staysafe #fighttogether #UequalU #AIDS

There are many effective ways to prevent or reduce the risk of HIV. It is essential to start treatment with HIV medication (called antiretroviral therapy or ART) as soon as possible after your diagnosis. When someone with HIV takes effective treatment, it reduces their viral load to undetectable levels. Visit our website https://drpounders.com/ or Call Us at 214-520-8833

Opportunistic infections (OIs) are infections that occur more often or are more severe in people with weakened immune systems than in people with healthy immune systems. People with weakened immune systems include people living with HIV. For people with HIV, the best protection against OIs is to take HIV medicines every day. For more information visit our site: https://drpounders.com/ or Call us: 214-520-8833

People who don't receive HIV treatment will typically proceed into three stages. But HIV medication can reduce or halt the rise of the disease. With the improvements in treatment, advance to Stage 3 is now less than in the initial days of HIV. For More Information Visit Our Website https://drpounders.com/ or Call Us at 214-520-8833

Ahead of World AIDS Day this Wednesday, the Royal Pharmaceutical Society has urged the government to widen access to pre-exposure prophylaxis (PrEP) by making it available through community pharmacies. It argues that such a move could drive down rates of HIV infection across Great Britain. Currently, the medicine - which offers almost total protection from HIV when taken as recommended prior to sex or injecting drugs - is available free of charge only through sexual health clinics. Calling on the government to engage with community pharmacies to improve public health, RPS president Claire Anderson said: "There is a clear opportunity to drive down rates of HIV infection by expanding provision of pre-exposure prophylaxis (PrEP) to community pharmacies and GP practices as part of the government's HIV Action Plan.

The Royal Pharmaceutical Society (RPS) Wales has welcomed proposals from the Welsh government to increase access to PrEP via community pharmacies for people at risk of HIV. The new HIV Action Plan for Wales consultation proposes a shared care model between primary care and specialist sexual health services to improve access to PrEP. Commenting on the proposal, chair of RPS in Wales Cheryl Way said: "Increasing access to the medicines has been a long-standing issue of concern for us at RPS and we're therefore delighted to see the proposals outlined by the Welsh government to develop a model which will enable PrEP to be provided by community pharmacies across Wales. "PrEP are highly effective medicines, that reduce the chances of getting HIV, as proven by the Welsh Government's three year PrEPARED study which found no new diagnoses of HIV among over 1,200 people taking PrEP in Wales. This is clear evidence that PrEP should be made as easily accessible as possible to those who need it.

Know the importance of HIV Testing Day and raise awareness and support people to suffer form HIV positive with customized rubber bracelets.